Trial Profile

Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Somatropin (Primary)
Indications Somatotropin deficiency
Focus Therapeutic Use
Sponsors GeneScience Pharmaceuticals

Most Recent Events

02 Jan 2025 Primary endpoint (Actual height of the patient after treatment compared with the mean height of the population and the standard deviation (SD) of the height of the population for that chronological age.) has been met, according to the Results published in the Clinical Endocrinology.
02 Jan 2025 Results published in the Clinical Endocrinology
04 Mar 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com